Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects

George B. Kudolo, Sheryl Dorsey, Janet Blodgett

    Research output: Contribution to journalArticle

    73 Citations (Scopus)

    Abstract

    Enhanced platelet function, particularly in response to collagen, is a common occurrence in diabetes that increases the risk of cardiovascular disease. Ginkgo biloba extract is ingested primarily to improve mental focus but it possesses a blood-thinning potential, which has not been well characterized. This study was designed to compare the effect of ingesting G. biloba extract on platelet aggregation in platelet-rich plasma (PRP) and prostanoid urinary excretion in healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). Before and after ingesting 120 mg of standardized G. biloba extract for 3 months, platelet aggregation was studied in PRP and urinary metabolites of thromboxane B2 (TXB2) and prostacyclin (PGI2) were measured. In healthy volunteers (age, 42±11 years; BMI, 28.4±4.8 kg/m2; n=28), the ingestion of G. biloba extract significantly increased fasting insulin and C-peptide (10±4 vs. 12±6 μU/ml, p<0.007 and 1.3±0.8 vs. 2.1±1.1 ng/ml, p<0.001, respectively) and significantly reduced collagen but not PAF-mediated platelet aggregation, converting 21 of 28 subjects with [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. This was accompanied by a reduction of 11-dehydro-TXB2 from 12.4±6.1 to 10.3±6.1 ng/mg Cr (p<0.04) and PGI2 metabolites (2,3-dinor-6-keto-PGF and 6-keto-PGF) from 2.2±0.8 to 1.8±0.8 ng/mg Cr (p<0.05). In the T2DM subjects (age, 54±8; BMI, 36.6±7.9 kg/m2; n=19), G. biloba ingestion did not affect pancreatic β-cell function but significantly reduced platelet aggregation, converting 16 of 19 [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. Unlike the healthy volunteers, this was not accompanied by a reduced urinary prostanoid excretion. G. biloba-induced reduction of both classes of prostanoid metabolites in healthy volunteers, but not in T2DM subjects, may suggest a nonselective inhibition of COX-1-mediated TXA2 in platelets and COX-2-mediated PGI2 production by the endothelial cells and perhaps platelet-enriched levels of arachidonic acid or COX-1 activity, or both, in T2DM subjects.

    Original languageEnglish (US)
    Pages (from-to)151-160
    Number of pages10
    JournalThrombosis Research
    Volume108
    Issue number2-3
    DOIs
    StatePublished - Nov 1 2002

    Fingerprint

    Ginkgo biloba
    Platelet Aggregation
    Prostaglandins
    Eating
    Epoprostenol
    Healthy Volunteers
    Blood Platelets
    Type 2 Diabetes Mellitus
    Platelet-Rich Plasma
    Collagen
    Phenotype
    Thromboxane B2
    C-Peptide
    Arachidonic Acid
    Fasting
    Cardiovascular Diseases
    Endothelial Cells
    Insulin

    Keywords

    • Diabetes
    • Ginkgo biloba
    • Platelet aggregation
    • Prostacyclin
    • Thromboxane

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Hematology

    Cite this

    Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. / Kudolo, George B.; Dorsey, Sheryl; Blodgett, Janet.

    In: Thrombosis Research, Vol. 108, No. 2-3, 01.11.2002, p. 151-160.

    Research output: Contribution to journalArticle

    @article{81454c1e40a94217a02f5d762a2f969b,
    title = "Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects",
    abstract = "Enhanced platelet function, particularly in response to collagen, is a common occurrence in diabetes that increases the risk of cardiovascular disease. Ginkgo biloba extract is ingested primarily to improve mental focus but it possesses a blood-thinning potential, which has not been well characterized. This study was designed to compare the effect of ingesting G. biloba extract on platelet aggregation in platelet-rich plasma (PRP) and prostanoid urinary excretion in healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). Before and after ingesting 120 mg of standardized G. biloba extract for 3 months, platelet aggregation was studied in PRP and urinary metabolites of thromboxane B2 (TXB2) and prostacyclin (PGI2) were measured. In healthy volunteers (age, 42±11 years; BMI, 28.4±4.8 kg/m2; n=28), the ingestion of G. biloba extract significantly increased fasting insulin and C-peptide (10±4 vs. 12±6 μU/ml, p<0.007 and 1.3±0.8 vs. 2.1±1.1 ng/ml, p<0.001, respectively) and significantly reduced collagen but not PAF-mediated platelet aggregation, converting 21 of 28 subjects with [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. This was accompanied by a reduction of 11-dehydro-TXB2 from 12.4±6.1 to 10.3±6.1 ng/mg Cr (p<0.04) and PGI2 metabolites (2,3-dinor-6-keto-PGF1α and 6-keto-PGF1α) from 2.2±0.8 to 1.8±0.8 ng/mg Cr (p<0.05). In the T2DM subjects (age, 54±8; BMI, 36.6±7.9 kg/m2; n=19), G. biloba ingestion did not affect pancreatic β-cell function but significantly reduced platelet aggregation, converting 16 of 19 [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. Unlike the healthy volunteers, this was not accompanied by a reduced urinary prostanoid excretion. G. biloba-induced reduction of both classes of prostanoid metabolites in healthy volunteers, but not in T2DM subjects, may suggest a nonselective inhibition of COX-1-mediated TXA2 in platelets and COX-2-mediated PGI2 production by the endothelial cells and perhaps platelet-enriched levels of arachidonic acid or COX-1 activity, or both, in T2DM subjects.",
    keywords = "Diabetes, Ginkgo biloba, Platelet aggregation, Prostacyclin, Thromboxane",
    author = "Kudolo, {George B.} and Sheryl Dorsey and Janet Blodgett",
    year = "2002",
    month = "11",
    day = "1",
    doi = "10.1016/S0049-3848(02)00394-8",
    language = "English (US)",
    volume = "108",
    pages = "151--160",
    journal = "Thrombosis Research",
    issn = "0049-3848",
    publisher = "Elsevier Limited",
    number = "2-3",

    }

    TY - JOUR

    T1 - Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects

    AU - Kudolo, George B.

    AU - Dorsey, Sheryl

    AU - Blodgett, Janet

    PY - 2002/11/1

    Y1 - 2002/11/1

    N2 - Enhanced platelet function, particularly in response to collagen, is a common occurrence in diabetes that increases the risk of cardiovascular disease. Ginkgo biloba extract is ingested primarily to improve mental focus but it possesses a blood-thinning potential, which has not been well characterized. This study was designed to compare the effect of ingesting G. biloba extract on platelet aggregation in platelet-rich plasma (PRP) and prostanoid urinary excretion in healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). Before and after ingesting 120 mg of standardized G. biloba extract for 3 months, platelet aggregation was studied in PRP and urinary metabolites of thromboxane B2 (TXB2) and prostacyclin (PGI2) were measured. In healthy volunteers (age, 42±11 years; BMI, 28.4±4.8 kg/m2; n=28), the ingestion of G. biloba extract significantly increased fasting insulin and C-peptide (10±4 vs. 12±6 μU/ml, p<0.007 and 1.3±0.8 vs. 2.1±1.1 ng/ml, p<0.001, respectively) and significantly reduced collagen but not PAF-mediated platelet aggregation, converting 21 of 28 subjects with [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. This was accompanied by a reduction of 11-dehydro-TXB2 from 12.4±6.1 to 10.3±6.1 ng/mg Cr (p<0.04) and PGI2 metabolites (2,3-dinor-6-keto-PGF1α and 6-keto-PGF1α) from 2.2±0.8 to 1.8±0.8 ng/mg Cr (p<0.05). In the T2DM subjects (age, 54±8; BMI, 36.6±7.9 kg/m2; n=19), G. biloba ingestion did not affect pancreatic β-cell function but significantly reduced platelet aggregation, converting 16 of 19 [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. Unlike the healthy volunteers, this was not accompanied by a reduced urinary prostanoid excretion. G. biloba-induced reduction of both classes of prostanoid metabolites in healthy volunteers, but not in T2DM subjects, may suggest a nonselective inhibition of COX-1-mediated TXA2 in platelets and COX-2-mediated PGI2 production by the endothelial cells and perhaps platelet-enriched levels of arachidonic acid or COX-1 activity, or both, in T2DM subjects.

    AB - Enhanced platelet function, particularly in response to collagen, is a common occurrence in diabetes that increases the risk of cardiovascular disease. Ginkgo biloba extract is ingested primarily to improve mental focus but it possesses a blood-thinning potential, which has not been well characterized. This study was designed to compare the effect of ingesting G. biloba extract on platelet aggregation in platelet-rich plasma (PRP) and prostanoid urinary excretion in healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). Before and after ingesting 120 mg of standardized G. biloba extract for 3 months, platelet aggregation was studied in PRP and urinary metabolites of thromboxane B2 (TXB2) and prostacyclin (PGI2) were measured. In healthy volunteers (age, 42±11 years; BMI, 28.4±4.8 kg/m2; n=28), the ingestion of G. biloba extract significantly increased fasting insulin and C-peptide (10±4 vs. 12±6 μU/ml, p<0.007 and 1.3±0.8 vs. 2.1±1.1 ng/ml, p<0.001, respectively) and significantly reduced collagen but not PAF-mediated platelet aggregation, converting 21 of 28 subjects with [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. This was accompanied by a reduction of 11-dehydro-TXB2 from 12.4±6.1 to 10.3±6.1 ng/mg Cr (p<0.04) and PGI2 metabolites (2,3-dinor-6-keto-PGF1α and 6-keto-PGF1α) from 2.2±0.8 to 1.8±0.8 ng/mg Cr (p<0.05). In the T2DM subjects (age, 54±8; BMI, 36.6±7.9 kg/m2; n=19), G. biloba ingestion did not affect pancreatic β-cell function but significantly reduced platelet aggregation, converting 16 of 19 [COL+/EPI+] platelets to the [COL-/EPI+] phenotype. Unlike the healthy volunteers, this was not accompanied by a reduced urinary prostanoid excretion. G. biloba-induced reduction of both classes of prostanoid metabolites in healthy volunteers, but not in T2DM subjects, may suggest a nonselective inhibition of COX-1-mediated TXA2 in platelets and COX-2-mediated PGI2 production by the endothelial cells and perhaps platelet-enriched levels of arachidonic acid or COX-1 activity, or both, in T2DM subjects.

    KW - Diabetes

    KW - Ginkgo biloba

    KW - Platelet aggregation

    KW - Prostacyclin

    KW - Thromboxane

    UR - http://www.scopus.com/inward/record.url?scp=0036878140&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0036878140&partnerID=8YFLogxK

    U2 - 10.1016/S0049-3848(02)00394-8

    DO - 10.1016/S0049-3848(02)00394-8

    M3 - Article

    C2 - 12590952

    AN - SCOPUS:0036878140

    VL - 108

    SP - 151

    EP - 160

    JO - Thrombosis Research

    JF - Thrombosis Research

    SN - 0049-3848

    IS - 2-3

    ER -